Algorithme Pharma at the AAPS NBC Meeting
San Diego, CA – May 19-21, 2014 – TABLETOP # 417

Algorithme Pharma is a clinical contract research organization (CRO) with over 20 years of experience. We provide services for the pharmaceutical, biotechnology and generic drug industries.

Click here to request a meeting.

Webinar:

Criteria for Performing a Scientifically Meaningful Lipemic Plasma Test during LC-MS/MS Bioanalytical Method Validation: Which Type to Choose?

Dr. Fabio Garofolo, VP Bioanalytical Services, Algorithme Pharma, will be presenting this webinar on: June 4th, 2014 at 10AM EDT.

For more information and to register, click here »

AAPS National Biotechnology Conference Poster Session

San Diego, CA (USA), May 19-21

May 20, 2014
10:00 AM to 2:00 PM

Liquid Chromatography-High Resolution Mass Spectrometry Bioanalytical Approach for the Quantification of Total Antibody-Drug-Conjugate (ADC, DAR ≥ 0) in Rat Plasma

Authors:
Jean-Nicholas Mess1, Suma Ramagiri2, Gary Impey2 and Fabio Garofolo1

1Algorithme Pharma Inc., Laval, Quebec, Canada
2AB Sciex, Concord, Ontario, Canada

Purpose:
Application of LC-HRMS for the determination of total concentration (DAR ≥ 0) of a model ADC in rat plasma.

more information
May 20, 2014
10:00 AM to 2:00 PM

Strategies to Eliminate Anti-Drug Antibody (ADA) Interference due to Immunogenicity on Large Molecule Quantification by LC-MS/MS

Authors:
Daniel Villeneuve, Jean-Nicholas Mess and Fabio Garofolo

Algorithme Pharma Inc., Laval, Québec, CANADA

Purpose:
Using Specific Extraction Conditions to Overcome the Impact of Anti-Drug Antibody (ADA) on LC-MS/MS Bioanalysis of a Large Therapeutic Peptide.

more information
May 20, 2014
10:00 AM to 2:00 PM

Application and Advantages of HRMS in the Quantification of Therapeutic Monoclonal Antibodies: The Rituximab Case Study

Authors:
Kevork Mekhssian, Jean-Nicholas Mess and Fabio Garofolo

Algorithme Pharma Inc., Laval, Québec, CANADA

Purpose:
Development of a very specific high resolution mass spectrometry (HRMS) method to quantify Rituximab in human plasma.

more information
May 20, 2014
10:00 AM to 2:00 PM

Quantification of Growth Hormone Receptor Antagonist Pegvisomant by LC-MS/MS in Rat Plasma: Method Development Considerations for PEGylated Proteins

Authors:
Jonathan R. St-Germain, Jean-Nicholas Mess and Fabio Garofolo

Algorithme Pharma Inc., Laval, Québec, CANADA

Purpose:
Quantification by UPLC-MS/MS of the PEGylated protein Pegvisomant in the ng/mL range without prior protein purification or enrichment.

more information
May 20, 2014
10:00 AM to 2:00 PM

Impact of Oxidative Modifications on the Quantification of Intact Therapeutic Proteins by High Resolution Mass Spectrometry

Authors:
Louis-Philippe Morin and Fabio Garofolo

Algorithme Pharma Inc., Laval, Québec, CANADA

Purpose:
HRMS instrument was used to detect and evaluate the impact of oxidative modifications on APO2L/TRAIL intact protein quantification.

more information
May 20, 2014
10:00 AM to 2:00 PM

Internal Standardization Approaches for the Quantification of a 25 kDa Fusion Protein to Support Early Stage Drug Development by LC-MS

Authors:
Jean-Nicholas Mess1, Karl-Rudolf Erlemann2, Jerzy Pieczykolan3, Sebastian Pawlak3 and Fabio Garofolo1

1Algorithme Pharma Inc., Laval, Quebec, Canada
2InSymbiosis, Montreal, Quebec, Canada
3Adamed Group, Czosnów, Poland

Purpose:
Evaluation on cost-effectiveness of readily available internal standards for the quantification of the therapeutic fusion protein VCTR4.0 by LC-MS.

more information

Research and Discovery

Scientific Innovation and Emerging Technologies in the Discovery and Development of Biotherapeutics (AAPS Emerging Technologies Action Program Committee)

May 20, 2014
Grande Ballroom A

Moderator:
Dr. Fabio Garofolo, Vice-President Bioanalytical Services, Algorithme Pharma will be chairing this session

Click here for details